EnvisionRx and Gilead Sciences Sign Exclusive Agreement to Help in the Fight Against Hepatitis C
27 January 2015 - 5:00AM
Business Wire
EnvisionRx®, a national, full-service pharmacy benefit
management (PBM) company, today announced a partnership with Gilead
Sciences Inc., a pioneer in the treatment of the Hepatitis C virus
(HCV), to provide availability to HCV infection treatments Sovaldi®
and Harvoni™ for EnvisionRx patients on an exclusive basis.
“EnvisionRx is committed to helping patients attain the most
effective drugs at affordable prices, and we are proud to be able
to offer our patients Sovaldi® and Harvoni™, the market leaders in
the treatment of HCV, ” said Dawn Sherman, President of EnvisionRx.
“The safety and efficacy profile of Gilead’s HCV products, coupled
with the most competitive pricing in the drug class, have
solidified EnvisionRx’s choice to place Gilead’s HCV products in an
exclusive and preferred formulary position. We believe our
comprehensive HCV approach will enable our patients to receive the
best available care.”
Consistent with PBM industry practice, exceptions for other
hepatitis C drugs will be allowed in some cases.
Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), is the first
once-daily single tablet regimen for the treatment of chronic
hepatitis C genotype 1 infection in adults. Sovaldi™ (sofosbuvir)
400 mg tablets, is a once-daily oral nucleotide analog polymerase
inhibitor for the treatment of chronic hepatitis C (CHC)
infection as a component of a combination antiviral treatment
regimen.
About EnvisionRx
Established in 2001, EnvisionRx is a national, full-service
pharmacy benefit management (PBM) company. EnvisionRx is part of a
group of healthcare management companies owned and operated by
Envision Pharmaceutical Holdings, LLC (EPH). EPH is a portfolio
company of TPG, a leading global private investment firm with $65
billion of assets under management. In addition to EnvisionRx, EPH
subsidiaries also include Envision Insurance Company, a fully
insured provider of Medicare Part D Plans nationally, Envision
Medical Solutions, LLC, an administrator of prescription savings
plans and prescription savings cards, Orchard Pharmaceutical
Services, LLC, a full-service mail-order and specialty drug
pharmacy, Design Rx, LLC, the market leader in cash-pay pharmacy
services for infertility and fertility products and Laker Software,
LLC, an innovative, market-leading provider of claims processing
systems and support services for prescription drug benefit
programs. EnvisionRx, which was founded on a commitment to provide
full disclosure in the PBM marketplace, promotes a transparent,
pass-through business model in which 100% of earned rebates,
discounts, and incentives are instantly credited at the point of
sale to customers, and for which EnvisionRx charges a low, flat
monthly management fee for most services. This translates into
significant savings for the company’s more than 13 million covered
individuals. The Company has been awarded the Utilization Review
Accreditation Commission (URAC) accreditations for PBM and Drug
Therapy Management annually since 2007. EnvisionRx is headquartered
in Twinsburg, OH, with offices in Fort Lauderdale, FL; Tampa, FL;
Canton, OH; Ogden, UT; Minneapolis, MN and El Dorado Hills, CA. For
more information about EnvisionRx visit www.envisionrx.com.
EnvisionRx is a registered trademark of Envision Pharmaceutical
Services, LLC.
About Gilead Sciences Inc.
Gilead Sciences is a biopharmaceutical company that
discovers, develops and commercializes innovative therapeutics in
areas of unmet medical need. The company’s mission is to advance
the care of patients suffering from life-threatening diseases
worldwide. Headquartered in Foster City, California, Gilead
has operations in North and South
America, Europe and Asia Pacific. U.S. Full
Prescribing Information for Harvoni and Sovaldi is available
at www.gilead.com. Harvoni and Sovaldi are trademarks or
registered trademarks of Gilead Sciences, Inc., and its
related companies.
EnvisionRxNick Vasilopoulos,
330-888-6926nvasilopoulos@envisionrx.com